Yuriko Itzel Sánchez-Zamora

Yuriko Itzel Sánchez-Zamora

Auto-generated profile, based on publicly available information

Yuriko Itzel Sánchez-Zamora

The Kidney and Urinary Tract Center, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus 43205, OH

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2008 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MFMarcos Flores-Alamo
Marcos Flores-Alamo
RSRafael Saavedra
Rafael Saavedra
RBRocio Bautista
Rocio Bautista
RVRubi Viedma
Rubi Viedma
ETEda Tenorio
Eda Tenorio
Miriam Rodriguez-SosaMiriam Rodriguez-Sosa
Miriam Rodriguez-Sosa
Macrophage migration inhibitory factor (MIF) exerts either a protective or a deleterious role in the immune response to different pathogens. We analyzed herein the role of MIF in the host control of toxoplasmosis using MIF −/− mice backcrossed to either the BALB/c or the C57BL/6 genetic backgrounds. Both, wild‐type (WT) BALB/c and MIF −/− BALB/c mice were susceptible to infection with highly virulent RH as well as moderately virulent ME49 strains of T. gondii .MIF −/− mice, however, showed greater liver damage and more brain cysts, produced less proinflammatory cytokines, and succumbed significantly faster than WT mice. Bone marrow‐derived dendritic cells (BMDCs) from MIF −/− mice produced less interleukin‐1β, interleukin‐12, and tumor necrosis factor‐α than WT BMDCs after stimulation with soluble Toxoplasma antigen (STAg). Similar observations were made in CD11c + low‐density cells isolated from the spleens of MIF −/− mice challenged with STAg. MIF −/− C57BL/6 mice succumbed to ME49 infection faster than their WT counterparts. C57BL/6 mice that succumbed to infection with the ME49 strain produced less MIF than resistant BALB/c mice similarly infected. Interestingly, an analysis of brains from patients with cerebral toxoplasmosis showed low levels of MIF expression. Together, these findings demonstrate that MIF plays a critical role in mediating host resistance against T. Gondii. —Flores, M., Saavedra, R., Bautista, R., Viedma, R., Tenorio, E. P., Leng, L., Sánchez, Y., Juárez, I., Satoskar, A. A., Shenoy, A. S., Terrazas, L. I., Bucala, R., Barbi J., Satoskar, A. R., Rodriguez‐Sosa, M. Macrophage migration inhibitory factor (MIF) is critical for the host resistance against Toxoplasma gondii. FASEB J. 22, 3661–3671 (2008)

2 January 2014 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
YSYuriko I. Sánchez-Zamora
Yuriko I. Sánchez-Zamora
Miriam Rodriguez-SosaMiriam Rodriguez-Sosa
Miriam Rodriguez-Sosa
Autoimmunity and chronic low-grade inflammation are hallmarks of diabetes mellitus type one (T1DM) and type two (T2DM), respectively. Both processes are orchestrated by inflammatory cytokines, including the macrophage migration inhibitory factor (MIF). To date, MIF has been implicated in both types of diabetes; therefore, understanding the role of MIF could affect our understanding of the autoimmune or inflammatory responses that influence diabetic pathology. This review highlights our current knowledge about the involvement of MIF in both types of diabetes in the clinical environment and in experimental disease models.

4 March 2010 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
YSYuriko Sanchez‐Zamora
Yuriko Sanchez‐Zamora
Luis I TerrazasLuis I Terrazas
Luis I Terrazas
AVAlonso Vilches‐Flores
Alonso Vilches‐Flores
ELEmmanuel Leal
Emmanuel Leal
IJImelda Juárez
Imelda Juárez
Miriam Rodriguez-SosaMiriam Rodriguez-Sosa
Miriam Rodriguez-Sosa
Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine involved in the pathogenesis of a variety of autoimmune inflammatory diseases. Here, we investigated the role of MIF in the pathogenesis of non‐insulin‐dependent diabetes mellitus (NIDDM) using MIF−/− mice and a mouse model of streptozotocin (STZ)‐induced NIDDM. Following single injection of STZ, MIF +/+ BALB/c mice showed a significant increase in blood glucose levels, developed polyuria, and succumbed to disease. In contrast, no such increase in blood glucose was observed in MIF −/− BALB/c mice treated with STZ. These mice produced significantly less inflammatory cytokines and resistin as compared with MIF +/+ mice and failed to develop clinical disease. Finally, oral administration of a smallmolecule MIF antagonist, CPSI‐1306, to outbred ICR mice following induction of NIDDM significantly lowered blood glucose levels in the majority of animals, which was also associated with a significant reduction in the levels of the proinflammatory cytokines IL‐6 and TNF‐α in the sera. Taken together, these results demonstrate that MIF is involved in the pathogenesis of NIDDM and is a therapeutic target to treat this disease.—Sanchez‐Zamora, Y., Terrazas, L. I., Vilches‐Flores, A, Leal, E., Jua´rez, I., Whitacre, C, Kithcart, A., Pruitt, J., Sielecki, T., Satoskar, A. R, Rodriguez‐Sosa, M. Macrophage migration inhibitory factor is a therapeutic target in treatment of non‐insulin‐dependent diabetes mellitus. FASEB J. 24, 2583–2590 (2010). www.fasebj.org

1 January 2010 in Journal of Biomedicine and Biotechnology
Verified
Journal Article
Open access
PDF file
YSYuriko Sanchez
Yuriko Sanchez
JRJuan de Dios Ruiz-Rosado
Juan de Dios Ruiz-Rosado
LVLibia Vega
Libia Vega
GEGuillermo Elizondo
Guillermo Elizondo
EEElizabeth Estrada-Muñiz
Elizabeth Estrada-Muñiz
Miriam Rodriguez-SosaMiriam Rodriguez-Sosa
Miriam Rodriguez-Sosa
The aryl hydrocarbon receptor (AhR) is part of a signaling system that is mainly triggered by xenobiotic agents. Increasing evidence suggests that AhR may regulate immunity to infections. To determine the role of AhR in the outcome of toxoplasmosis, we used AhR-/- and wild-type (WT) mice. Following an intraperitoneal infection withToxoplasma gondii(T. gondii), AhR-/- mice succumbed significantly faster than WT mice and displayed greater liver damage as well as higher serum levels of tumor necrosis factor (TNF)-α, nitric oxide (NO), and IgE but lower IL-10 secretion. Interestingly, lower numbers of cysts were found in their brains. Increased mortality was associated with reduced expression of GATA-3, IL-10, and 5-LOX mRNA in spleen cells but higher expression of IFN-γmRNA. Additionally, peritoneal exudate cells from AhR-/- mice produced higher levels of IL-12 and IFN-γbut lower TLR2 expression than WT mice. These findings suggest a role for AhR in limiting the inflammatory response during toxoplasmosis.

6 September 2016 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
YSYuriko Itzel Sánchez-Zamora
Yuriko Itzel Sánchez-Zamora
IJImelda Juarez-Avelar
Imelda Juarez-Avelar
AMAlicia Vázquez Mendoza
Alicia Vázquez Mendoza
Marcia HiriartMarcia Hiriart
Marcia Hiriart
Miriam Rodriguez-SosaMiriam Rodriguez-Sosa
Miriam Rodriguez-Sosa
Macrophage migration inhibitory factor (Mif) is highly expressed in type 1 diabetes mellitus (T1DM). However, there is limited information about how Mif influences the activation of macrophages (Mφ) and dendritic cells (DC) in T1DM. To address this issue, we induced T1DM by administering multiple low doses of streptozotocin (STZ) toMif−/−or wild-type (Wt) BALB/c mice. We found thatMif−/−mice treated with STZ (Mif−/−STZ) developed lower levels of hyperglycemia, inflammatory cytokines, and specific pancreatic islet antigen- (PIAg-) IgG and displayed reduced cellular infiltration into the pancreatic islets compared to Wt mice treated with STZ (WtSTZ). Moreover, Mφand DC fromMif−/−STZ displayed lower expression of MHC-II, costimulatory molecules CD80, CD86, and CD40, Toll-like receptor- (TLR-) 2, and TLR-4 than WtSTZ. These changes were associated with a reduced capacity of Mφand DC fromMif−/−STZ to induce proliferation in ovalbumin-specific T cells. All the deficiencies observed inMif−/−STZ were recovered by exogenous administration of recombinant Mif. These findings suggest that Mif plays a role in the molecular mechanisms of Mφand DC activation and drives T cell responses involved in the pathology of T1DM. Therefore, Mif is a potential therapeutic target to reduce the pathology of T1DM.

18 January 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LSLaura Schwartz
Laura Schwartz
MBM. Skye Bochter
M. Skye Bochter
ASAaron Simoni
Aaron Simoni
KBKristin Bender
Kristin Bender
JRJuan de Dios Ruiz Rosado
Juan de Dios Ruiz Rosado
JSJohn Spencer
John Spencer
With the emergence of antibiotic-resistant bacteria, innovative approaches are needed for the treatment of urinary tract infections. Boosting antimicrobial peptide expression may provide an alternative to antibiotics. Here, we developed reporter cell lines and performed a high-throughput screen of clinically used drugs to identify compounds that boost ribonuclease 4 and 7 expression (RNase 4 and 7), peptides that have antimicrobial activity against antibiotic-resistant uropathogens. This screen identified histone deacetylase (HDAC) inhibitors as effective RNase 4 and RNase 7 inducers. Validation studies in primary human kidney and bladder cells confirmed pan-HDAC inhibitors as well as the HDAC class I inhibitor, MS-275, induce RNase 4 and RNase 7 to protect human kidney and bladder cells from uropathogenic Escherichia coli . When we administered MS-275 to mice, RNase 4 and 7 expression increased and mice were protected from acute transurethral E. coli challenge. In support of this mechanism, MS-275 treatment increased acetylated histone H3 binding to the RNASE4 and RNASE7 promoters. Overexpression and knockdown of HDAC class I proteins identified HDAC3 as a primary regulator of RNase 4 and 7. These results demonstrate the protective effects of enhancing RNase 4 and RNase 7, opening the door to repurposing medications as antibiotic conserving therapeutics for urinary tract infection.